Implantable vagal stimulator led to benefit in TNF-inadequate responder RA in this sham-controlled double-blind RCT (RESET-RA study) - 82% off b/tsDMARDs at 12mo - also with benefit to control group after crossover at 3mo to an active device #ACR25 1675 @RheumNow https://t.co/yYwWCKm6HF

• https://x.com/drdavidliew/status/1982878593199026656/photo/1

In the SERENA study (n=292), secukinumab reduced PsA incidence to 0.49/100 PY over 5 years in PsO patients with nail involvement, an ~82% drop vs historic non-biologic rates (2.7/100 PY). 98.3% remained PsA-free; PASI 90 achieved in 63%. Abstract#1463 @RheumNow #ACR25 https://t.co/ySOuFJiwge

• https://x.com/synovialjoints/status/1982869912092619021/photo/1

Beyond biologics: RA meets bioelectric medicine. In RESET-RA, TNFi inadequate response or intolerant (n=124), vagus nerve stimulation led to significant & durable improvement 🔹 ACR20 3mo: 42% active vs 18% sham (p=0.0057) 🔹 Benefits through 12mo @RheumNow #ACR25 A#1675

Short chain fatty acids (SCFA) and the relevant microbiome have been linked to RA development and severity. Study of monozygotic twins, where only one has RA, two diff cohorts: lower SCFA lower SCFA microbiome Biomarkers, or even therapeutic target? #ACR25 ABST0442 @RheumNow https://t.co/HW1YfkfOG3

• https://x.com/drdavidliew/status/1982856625670238388/photo/1

Screening for ILD in RA patients: CXR and PFTs by themselves are close to a waste of time. When it comes to screening (high-risk) RA patients, it’s HRCT (or lung USS) or nothing really. (in keeping with EULAR, ACR guidelines) #ACR25 ABST1335 @RheumNow https://t.co/XBDxLwYsAT

• https://x.com/drdavidliew/status/1982854635577848230/photo/1

England et al. Predictors of progression RA-ILD - UIP pattern (HR 1.46), current (HR 1.98) and former (HR 1.60) smoking, age (HR 1.03). @RheumNow #ACR25 Abstr#1308 https://t.co/IvQo8Istta

• https://x.com/RichardPAConway/status/1982854555105947705/photo/1

Mease et al. What agent to use after failure of first TNFi in PsA. Real world study, 320 patients. Switching to upadacitinib led to better joint responses than second TNFi or IL17i @RheumNow #ACR25 Abstr#1453 https://t.co/SQnN0skw7r

• https://x.com/RichardPAConway/status/1982853045043298598/photo/1

What can we use to better predict MACE in RA patients? ESPOIR cohort showed value of two cardiac biomarkers: - hs-cTnT - soluble ST2 Combined, predicted MACE even after adjusting for disease activity/traditional CV RF. We need something like this! #ACR25 ABST1334 @RheumNow https://t.co/EUNDuuMaYD

• https://x.com/drdavidliew/status/1982852265397653571/photo/1

Loarce et al. Poor performance of CXR and PFT in diagnosing RA-ILD (compared to HRCT). Message is, if you think they have RA-ILD, you need to do CT. @RheumNow #ACR25 Abstr#1335 https://t.co/eeSTf72mvM

• https://x.com/RichardPAConway/status/1982852038548406493/photo/1

Getting RA patients into remission: have we plateaued? @MayoClinic data: early and later into the biologic era, and still median time to RA remission is >3y Surely we can aspire to more? Let’s target barriers to implementing better #ACR25 @ElHasbaniG @MyasoedovaElena @RheumNow https://t.co/JLTuL5cIet

• https://x.com/drdavidliew/status/1982850367370211807/photo/1

Pope @Janetbirdope et al. Parenteral (IM and/or IA) superior to oral steroids in early RA. Better discontinuation of steroids with no difference in need for advanced therapies. @RheumNow #ACR25 Abstr#1355 #ACRbest https://t.co/OyvnzEGlLE

• https://x.com/RichardPAConway/status/1982845746950164581/photo/1

After At-risk RA, time to discuss At-risk PsA patients ARP-PsA Prospective cohort 1400+ pts 8.4% met ARP-PsA criteria (arthralgia + Fam Hx +Pso, not referred via Dermatology) Risk factors: Pso >15 years Pso + Family Hx US synovitis/enthesitis At 1 yr follow-up 30% progressed https://t.co/ZY2ezh8nZN

• https://x.com/AurelieRheumo/status/1982842237986787364/photo/1
• https://x.com/AurelieRheumo/status/1982842237986787364/photo/1

Kuzkina et al. Efficacy of IL-6i with olokizumab on depression in RA. There appear to be some benefit but anti-depressants still needed. Group 1 is olokizumab alone, other 2 groups have anti-depressants also. @RheumNow #ACR25 Abstr#1323 https://t.co/h2ExYQgKTL

• https://x.com/RichardPAConway/status/1982840462747587012/photo/1

Rural RA care looks different but not less intensive: DMARD and GC use matched urban rates, yet rural pts often managed by PCPs had twice the opioid use. ACR's Rheum for Primary Care resource can help address access gap and improve RA care @RheumNow #ACR25 Abstract#1025

NEREA registry study on mortality in progressive pulmonary fibrosis in SARD-ILD. 158 patients. Median survival 7.8 years. DMARD use associated improved mortality. @RheumNow #ACR25 Abstr#1024 https://t.co/rK1caGi2r4

• https://x.com/RichardPAConway/status/1982833416073625649/photo/1